Consistent adherence to sodium-glucose cotransporter 2 (SGLT2) inhibitors in individuals with type 2 diabetes reduces the risk of hospitalization, supporting targeted interventions to improve medication-taking behavior.
Susan dosReis, PhD
Advertisement
Articles by Susan dosReis, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Medicare GLP-1 Bridge Launches, but Who Actually Qualifies?
2
FDA Advisory Committee Supports Moderna mRNA Flu Vaccine Review
3
Online GLP-1 Sellers Often Skip Clinician Oversight
4
Early Treatment Succeeds in CRC With Next-Generation KRAS Inhibitor Calderasib Plus Cetuximab Combo
5